Regeneron Pharmaceuticals (NASDAQ:REGN) Now Covered by Analysts at Citigroup

Investment analysts at Citigroup initiated coverage on shares of Regeneron Pharmaceuticals (NASDAQ:REGN) in a report released on Thursday, MarketBeat.com reports. The firm set a “neutral” rating and a $895.00 price target on the biopharmaceutical company’s stock. Citigroup’s target price would indicate a potential upside of 18.26% from the stock’s current price.

Other research analysts also recently issued research reports about the stock. Evercore ISI cut their target price on shares of Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating on the stock in a research report on Thursday, October 24th. Oppenheimer cut their price objective on shares of Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating on the stock in a research report on Wednesday, November 6th. Guggenheim lifted their price objective on shares of Regeneron Pharmaceuticals from $1,180.00 to $1,300.00 and gave the stock a “buy” rating in a research report on Friday, August 2nd. TD Cowen lifted their price objective on shares of Regeneron Pharmaceuticals from $1,030.00 to $1,200.00 and gave the stock a “buy” rating in a research report on Tuesday, July 23rd. Finally, BMO Capital Markets cut their price objective on shares of Regeneron Pharmaceuticals from $1,300.00 to $1,190.00 and set an “outperform” rating on the stock in a research report on Friday, November 1st. One analyst has rated the stock with a sell rating, four have assigned a hold rating and nineteen have given a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $1,099.55.

Regeneron Pharmaceuticals Trading Down 3.3 %

NASDAQ REGN opened at $756.81 on Thursday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.46 and a current ratio of 5.28. The company has a market capitalization of $83.17 billion, a price-to-earnings ratio of 18.93, a price-to-earnings-growth ratio of 3.04 and a beta of 0.15. The company’s 50-day simple moving average is $992.70 and its two-hundred day simple moving average is $1,033.92. Regeneron Pharmaceuticals has a one year low of $753.69 and a one year high of $1,211.20.

Insider Activity at Regeneron Pharmaceuticals

In related news, CFO Christopher R. Fenimore sold 5,680 shares of the business’s stock in a transaction on Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the completion of the transaction, the chief financial officer now directly owns 15,305 shares in the company, valued at $18,447,575.65. The trade was a 27.07 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 7.48% of the company’s stock.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

Several large investors have recently made changes to their positions in the company. Rakuten Securities Inc. increased its holdings in Regeneron Pharmaceuticals by 380.0% in the 3rd quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 19 shares in the last quarter. Stephens Consulting LLC purchased a new stake in Regeneron Pharmaceuticals in the 2nd quarter worth $26,000. Sachetta LLC increased its holdings in Regeneron Pharmaceuticals by 71.4% in the 2nd quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 10 shares in the last quarter. FSA Wealth Management LLC purchased a new stake in Regeneron Pharmaceuticals in the 3rd quarter worth $26,000. Finally, Crewe Advisors LLC purchased a new stake in Regeneron Pharmaceuticals in the 1st quarter worth $28,000. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.